Articles

Zyprexa era comes to an end for Lilly

On Oct. 24, the U.S. Food and Drug Administration approved the first generic versions of Eli Lilly and Co.’s best-seller, ending 15 years of highly lucrative sales.

Read More

Critics: Patent overhaul could hurt startups

When the Senate passed legislation last week overhauling the U.S. patent system, large multinational corporations like Eli Lilly and Co. rejoiced. But small-business advocates cried foul, saying the changes would put innovative startups at a disadvantage.

Read More

Growth in drug spending to slow as generics rise

The annual growth rate in spending on drugs may be cut in half over the next five years as people opt for less expensive generic medicines over brand-name treatments, a health-care research group said Wednesday, highlighting the challenge pharmaceutical firms like Eli Lilly and Co. are facing.

Read More

Firm joins race with IU autism drug

The Indiana University School of Medicine has licensed a pediatric psychiatrist’s patent on
an alcohol-dependency drug that the doctor discovered improves the language and social skills of autism patients. IU has licensed the patent to Indianapolis-based Confluence Pharmaceuticals Inc.

Read More

Lechleiter: After the deluge, we’ll be fine

Eli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly will be just fine after it has sustained the damage of the next three years.

Read More

Dow Chemical moves toward engineered corn patent

Dow Chemical Co.'s agricultural division said it has taken the next step toward gaining international patent rights for its new strain of genetically engineered corn that it says will help farmers battle a new strain of “super-weeds.”

Read More

Emerging markets give Lilly hope in patent crunch

In a kind of alternate drug universe, sales of Eli Lilly and Co.’s ghosts of blockbusters past are soaring in China—prompting the drugmaker to pour money into emerging markets in an attempt to prop up revenue.

Read More